Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$29.68 +1.50%

+$0.50 today

Market cap
$1.78B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.60M

Average 1.11M

AGIO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Agios Pharmaceuticals, Inc.NASDAQ: AGIO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue grows, but more slowly than its trailing trend

Q1 FY2026 cost of revenue of $2.68M rose 13.5% year over year, behind the +58.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 14.7% from the prior quarter. Over 3 fiscal years it compounded at +89.1% a year.

Context

  • Cost of revenue amounted to 21.3% of revenue in FY2025, up 9.9 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +13.5% toward the trailing-twelve-month pace of +58.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.68M-14.7% QoQ
Last fiscal yearDec 2025
$11.52M+176.6% YoY
LTMMar 2026
$11.84M+58.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.5%——
1 year+176.6%——
3-year CAGR+89.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
11.52M USD
Year-over-year change
+176.6%
4-year CAGR
-11.5%

Cost of Revenue vs competitors

How AGIO compares with its peers on the latest reported figures

  • AGIO's LTM Mar 2026 cost of revenue of $11.84M is the 6th highest of the 7 companies compared; the peer median is $111.55M.
  • Its year-over-year change of +58.0% is the 3rd highest of 6, against a peer median of +32.9%.
  • Cost of revenue amounts to 17.9% of revenue for AGIO, versus a peer median of 17.9%.
AGIO Competitors Peer median
Cost of Revenue for AGIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$719.42M +4201.4%+42.5%76.5%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$180.19M +250.5%+17.1%17.9%
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026$113.1M +25.6%+101.1%18.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$109.99M +25.2%+56.7%16.4%
PHARPharming Group N.V.LTM Mar 2026$46.97M +32.9%+37.5%12.7%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$11.84M +58.0%+89.1%17.9%
IRONDisc Medicine, Inc.LTM Sep 2026$0 ———
Peer median (excluding AGIO) $111.55M+32.9%+42.5%17.9%

Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue014.24M26.82M36.5M54.03M
Cost of Revenue18.78M1.7M9.5M4.17M11.52M
Gross Profit(18.78M)12.54M17.32M32.33M42.51M
Gross Margin—88.0%64.6%88.6%78.7%
Research & Development256.97M279.91M288.9M301.29M334.36M
Selling, General & Admin121.45M121.67M119.9M156.78M180.28M
Operating Expenses359.64M401.58M408.81M458.07M514.64M
Depreciation & Amortization18.78M8.56M6.62M5.65M5.18M
EBITDA(337.73M)(223.24M)(345.47M)723.62M(408.62M)
EBITDA Margin—-1567.7%-1287.9%1982.6%-756.3%
Operating Income(378.42M)(389.05M)(391.49M)(425.74M)(472.13M)
Operating Margin—-2732.1%-1459.5%-1166.5%-873.9%
Interest Income836K12.79M33.34M48.08M56.38M
Interest Expense00000
Other Income / Expenses21.91M157.25M39.4M1.14B58.34M
Income Before Tax(356.51M)(231.8M)(352.09M)717.97M(413.8M)
Pre-Tax Margin—-1627.8%-1312.6%1967.1%-765.9%
Income Tax Expense00044.24M(1.02M)
Net Income1.6B(231.8M)(352.09M)673.73M(412.78M)
Net Margin—-1627.8%-1312.6%1845.9%-764.0%
EPS (Basic)(6.36)(4.23)(6.33)11.86(7.12)
EPS (Diluted)(6.36)(4.23)(6.33)11.64(7.12)
Weighted Avg Shares60.45M54.79M55.65M56.81M57.97M
Weighted Avg Shares (Diluted)60.45M54.79M55.65M57.89M57.97M

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.